Domů › Rakovina prsu › Oregon › Portland
Klinické studie Rakovina prsu v Portland, OR
33 studií pro Rakovina prsu hledá účastníky v lokalitách v Portland a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Probíhá náborFáze 3
- Oregon Health & Science University, Knight Cancer Institute, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- Oregon Health & Science University (OHSU), Portland
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Probíhá náborFáze 3
- Northwest Cancer Specialists, Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · Vzdálenost 12 mi
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Probíhá náborFáze 1/2
- Compass Oncology - Rose Quarter Cancer Center, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Probíhá náborFáze 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Probíhá náborFáze 3
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Probíhá náborFáze 2
- Oregon Health and Science University, Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Probíhá náborFáze 3
- Clinical Trial Site, Portland
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Probíhá náborFáze 3
- Oregon Health and Science University, Portland
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Probíhá náborFáze 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Probíhá náborFáze 3
- Providence Portland Medical Center, Portland
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Probíhá náborFáze 3
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Probíhá náborFáze 1
- Providence Portland Medical Center, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Probíhá náborFáze 1
- Providence Cancer Institute, Portland
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Probíhá náborFáze 3
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Probíhá náborFáze 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- a dalších 2
A Study of MGC026 in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- Providence Cancer Institute, Portland
E-Mindfulness Approaches for Living After Breast Cancer
Probíhá náborFáze 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- a dalších 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Probíhá náborFáze 1/2
- Compass Oncology - Rose Quarter, Portland
Identifying and Caring for Individuals With Inherited Cancer Syndrome
Probíhá náborVítáni zdraví dobrovolníci
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Providence Cancer Institute Franz Clinic, Portland
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Probíhá náborFáze 2
- OHSU Knight Cancer Institute, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Probíhá náborFáze 2
- Oregon Health & Science Institute (OHSU), Portland
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Probíhá náborFáze 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- a dalších 1
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Probíhá náborObservační studie
- Kaiser Permanente Northwest, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Portland
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Probíhá náborFáze 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Probíhá náborObservační studie
- Legacy Good Samaritan Medical Center, Portland
EMBRACE: Exercising Together
Probíhá náborFáze 2Vítáni zdraví dobrovolníci
- OHSU Knight Cancer Institute, Portland
Studie Rakovina prsu v jiných městech
- New York City, NY136 studií
- Houston, TX126 studií
- Boston, MA112 studií
- Nashville, TN81 studií
- Los Angeles, CA73 studií
- Edison, NJ68 studií
- St. Louis, MO64 studií
- Queens, NY64 studií
- Durham, NC64 studií
- Chicago, IL59 studií
- Philadelphia, PA56 studií
- Dallas, TX55 studií
Další studie v Portland
- Nemalobuněčný plicní karcinom46 studií
- Rakovina (všechny typy)34 studií
- Rakovina prostaty33 studií
- Metastatický karcinom29 studií
- Kolorektální karcinom28 studií
- Rakovina vaječníků27 studií
- Rakovina plic26 studií
- Akutní myeloidní leukemie25 studií
- Rakovina endometria24 studií
- Squamózní buněčný karcinom hlavy a krku19 studií
- Rakovina slinivky břišní19 studií
- Srdeční selhání17 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.